Literature DB >> 12715436

[Expression patterns in isoforms of vascular endothelial growth-factors in tissue samples of vulval cancer T1 N2M0 stage].

Bogdan Michalski1, Urszula Mazurek, Anita Olejek, Tomasz Loch, Michał Graniczka, Ryszard Poreba, Tadeusz Wilczok.   

Abstract

OBJECTIVES: The aim of the study was estimating the expression of isoforms of mRNA vascular endothelial growth factor: VEGF121, VEGF145, VEGF165, VEGF183, VEGF189, VEGF206, in tissue samples of vulvar cancer, normal and inguinal lymph nodes metastases.
MATERIALS AND METHODS: The material for this investigation of expression of mRNA selected genes was 4 tissue specimens from women with vulvar cancer T1N2M0. The method used for quantitative determination of the numbers of mRNA copies of selected genes was the QRT-PCR and QPCR technique, with the use of an ABI PRISM 7700 (TaqMan) sequence detector. The nucleotide sequence for starters and probes for quantitative RT-PCR was designed with the use of the Primer Express Version 1.0 ABI PRISM software.
RESULTS: Expression of all mRNA isoforms VEGF was found in the samples. The number of mRNA copies obtained in 1 microgram total mRNA extract of the genes examined in tissue sections with various pathomorphology were clearly differentiated.
CONCLUSIONS: Expression profile of aforementioned genes indicated a definitive relationship between vascular endothelial growth factor isoform and vulvar cancer. These findings provide evidence that the expression pattern of mRNA VEGF isoform should find broad applications in clinical and research settings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715436

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  1 in total

1.  Post-transcriptional modifications of VEGF-A mRNA in non-ischemic dilated cardiomyopathy.

Authors:  Jacek Kowalczyk; Dorota Domal-Kwiatkowska; Urszula Mazurek; Michał Zembala; Bogdan Michalski; Marian Zembala
Journal:  Cell Mol Biol Lett       Date:  2007-02-12       Impact factor: 5.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.